systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-138Research ArticleСТАТЬИARTICLESИнгибиторы ангиотензинпревращающего фермента в терапии артериальной гипертонии: плейотропные эффекты и дополнительные клинические преимуществаАдашеваТ. В.noemail@neicon.ruЗадионченкоВ. С.noemail@neicon.ruМациевичМ. В.noemail@neicon.ruГОУ ВПО МГМСУ РосздраваRussian Federation200823122022525559Copyright © Адашева Т.В., Задионченко В.С., Мациевич М.В., 20222022Адашева Т.В., Задионченко В.С., Мациевич М.В.Адашева Т.В., Задионченко В.С., Мациевич М.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/138ReferencesGuidelines for the management of arterial hypertension. Guidelines Committee 2007. European Society of Hypertension. European Society of Cardiology. J Hypertension 2007; 25: 1105-87.Guidelines for the management of arterial hypertension. Guidelines Committee 2007. European Society of Hypertension. European Society of Cardiology. J Hypertension 2007; 25: 1105-87.Остроумова О.Д., Дубинская Р.Э. Дисфункция эндотелия при сердечно-сосудистых заболеваниях (по материалам ХIII Европейской конференции по артериальной гипертензии). Кардиология. 2005; 2: 59-62.Остроумова О.Д., Дубинская Р.Э. Дисфункция эндотелия при сердечно-сосудистых заболеваниях (по материалам ХIII Европейской конференции по артериальной гипертензии). Кардиология. 2005; 2: 59-62.Петрищев Н.Н., Власов Т.Д. Физиология и патофизиология эндотелия. Дисфункция эндотелия. Причины, механизмы. Фармакологическая коррекция. Под ред. Н.Н.Петрищева. СПб.: Изд-во СПбГМУ, 2003; 4-38.Петрищев Н.Н., Власов Т.Д. Физиология и патофизиология эндотелия. Дисфункция эндотелия. Причины, механизмы. Фармакологическая коррекция. Под ред. Н.Н.Петрищева. СПб.: Изд-во СПбГМУ, 2003; 4-38.Nosratola D Vaziri, Bernardo RodrТguez-Iturbe. Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nature Clin Practice Nephrol 2006; 2 (10): 582-93.Nosratola D Vaziri, Bernardo RodrТguez-Iturbe. Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nature Clin Practice Nephrol 2006; 2 (10): 582-93.Guo X, Liu WL, Chen LW, Guo ZG. High glucose impairs endothelium-dependent relaxation in rabbit aorta. Acta Pharmacol 2000; Sin 21: 169-73.Guo X, Liu WL, Chen LW, Guo ZG. High glucose impairs endothelium-dependent relaxation in rabbit aorta. Acta Pharmacol 2000; Sin 21: 169-73.Jameson M, Dai FX, Luster T et al. Endothelium derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. Hypertension 1993; 21: 280-8.Jameson M, Dai FX, Luster T et al. Endothelium derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. Hypertension 1993; 21: 280-8.Kumar KW, Das UM. Are free radicals involved in the pathobiology of human essential hypertension? Free Rad Res Commun 1993; 19: 59-66.Kumar KW, Das UM. Are free radicals involved in the pathobiology of human essential hypertension? Free Rad Res Commun 1993; 19: 59-66.Ярема Н.И., Коновалова Г.Г., Ланкин В.З. Изменение активности антиоксидантных ферментов у больных гипертонической болезнью. Кардиология. 1992; 32 (3): 46-8.Ярема Н.И., Коновалова Г.Г., Ланкин В.З. Изменение активности антиоксидантных ферментов у больных гипертонической болезнью. Кардиология. 1992; 32 (3): 46-8.Griengling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity incultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.Griengling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity incultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.Sohn HY, Raff U, Hoffman A et al. Differential role of angiotensin II receptor subtypes on endothelial O2-formation. Br J Pharmacol 2000; 131: 667-72.Sohn HY, Raff U, Hoffman A et al. Differential role of angiotensin II receptor subtypes on endothelial O2-formation. Br J Pharmacol 2000; 131: 667-72.Laursen JB, Rajagopalan S, Galis Z et al. Role of superoxide in angiotensin II-indused but not catecholamine-indused hypertension. Circulation 1997; 95: 588-93.Laursen JB, Rajagopalan S, Galis Z et al. Role of superoxide in angiotensin II-indused but not catecholamine-indused hypertension. Circulation 1997; 95: 588-93.Pepine CJ, Celermajer DS, Drexler H. Vascular health as a therapeutic tagert in cardiovascular disease. University of Florida 1998; 42.Pepine CJ, Celermajer DS, Drexler H. Vascular health as a therapeutic tagert in cardiovascular disease. University of Florida 1998; 42.Scholkens BA, Unger T. ACE Inhibitors, Endothelial function and Atherosclerosis. Amsterdam Media Medica Publications. March 1993; 36.Scholkens BA, Unger T. ACE Inhibitors, Endothelial function and Atherosclerosis. Amsterdam Media Medica Publications. March 1993; 36.Ulfendahl HR, Aurell M. Renin-Angiotensin. Portland Press. London 1998; 305.Ulfendahl HR, Aurell M. Renin-Angiotensin. Portland Press. London 1998; 305.Creager MA, Roddy MA. Effects of captopril and enalapril on endothelial function in hypertensive patients. Hypertension1994; 24: 499-505.Creager MA, Roddy MA. Effects of captopril and enalapril on endothelial function in hypertensive patients. Hypertension1994; 24: 499-505.Anderson TJ, Overhiser RW, Haber H, Charbonneau FA. Comparitive study of four anti-hypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol 1998; 31 (2, suppl. A): 327.Anderson TJ, Overhiser RW, Haber H, Charbonneau FA. Comparitive study of four anti-hypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol 1998; 31 (2, suppl. A): 327.Mancini GBJ, Henry G, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65.Mancini GBJ, Henry G, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65.Чазов Е.И., Беленков Ю.Н., Оганов Р.Г. и др. Информационное письмо. ВНОК. Результаты исследования EUROPA: периндоприл показан больным стабильной ИБС. Фарматека. 2004; 2: 14-5.Чазов Е.И., Беленков Ю.Н., Оганов Р.Г. и др. Информационное письмо. ВНОК. Результаты исследования EUROPA: периндоприл показан больным стабильной ИБС. Фарматека. 2004; 2: 14-5.Dagenais GR, Pogue J, Fox K et al Angiotensin-converting-enzyme ingibitors in stable vascular disease without left ventrtcular systolic disfunction or heart failure: a combined analyseis of three trials. Lancet 2006; 368 (9535): 581-8.Dagenais GR, Pogue J, Fox K et al Angiotensin-converting-enzyme ingibitors in stable vascular disease without left ventrtcular systolic disfunction or heart failure: a combined analyseis of three trials. Lancet 2006; 368 (9535): 581-8.HOPE study. N Engl J Med 2000; 342: 145-53.HOPE study. N Engl J Med 2000; 342: 145-53.Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-8.Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-8.Tikellis C, Wookey P, Candido R. Improved islet morphology after blockade of the rennin-angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-97.Tikellis C, Wookey P, Candido R. Improved islet morphology after blockade of the rennin-angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-97.Califf RM. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J 2003;5: 13-8.Califf RM. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J 2003;5: 13-8.Punzi HA et al. Antyhypertensive and Lipid- Lowering Heart Attack Treal Study; Trinity Hypertension Research Institute. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Treal Study. Curr Hypertens Rep 2004; 6: 106-10.Punzi HA et al. Antyhypertensive and Lipid- Lowering Heart Attack Treal Study; Trinity Hypertension Research Institute. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Treal Study. Curr Hypertens Rep 2004; 6: 106-10.Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-6.Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-6.Mancia G, Bombelli M, Corrao G et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40-7.Mancia G, Bombelli M, Corrao G et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40-7.Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453-8.Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453-8.Небиеридзе Д.В. Ингибиторы АПФ: метаболические и сосудистые эффекты. РМЖ. 2005; 15: 3-6.Небиеридзе Д.В. Ингибиторы АПФ: метаболические и сосудистые эффекты. РМЖ. 2005; 15: 3-6.Аметов А.С., Губина Е.В. Исследование метаболических эффектов Берлиприла-5 у больных инсулинонезависимым сахарным диабетом и артериальной гипертонией. Тер. арх. 1998; 8: 12-4.Аметов А.С., Губина Е.В. Исследование метаболических эффектов Берлиприла-5 у больных инсулинонезависимым сахарным диабетом и артериальной гипертонией. Тер. арх. 1998; 8: 12-4.Прохорович Е.А., Ткачева О.Н., Адаменко А.Н. и др., Артериальная гипертония у женщин репродуктивного возраста. РМЖ. 2007; 15, 20: 1440-2.Прохорович Е.А., Ткачева О.Н., Адаменко А.Н. и др., Артериальная гипертония у женщин репродуктивного возраста. РМЖ. 2007; 15, 20: 1440-2.
The authors declare that there are no conflicts of interest present.